- Home
- ANGO vs CAPR Comparison
ANGO vs CAPR Comparison
Compare ANGO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- CAPR
- Stock Information
- Founded
- ANGO 1988
- CAPR 2005
- Country
- ANGO United States
- CAPR United States
- Employees
- ANGO N/A
- CAPR N/A
- Industry
- ANGO Medical/Dental Instruments
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANGO Health Care
- CAPR Health Care
- Exchange
- ANGO Nasdaq
- CAPR Nasdaq
- Market Cap
- ANGO 400.8M
- CAPR 324.6M
- IPO Year
- ANGO 2004
- CAPR N/A
- Fundamental
- Price
- ANGO $11.73
- CAPR $6.08
- Analyst Decision
- ANGO Strong Buy
- CAPR Strong Buy
- Analyst Count
- ANGO 3
- CAPR 6
- Target Price
- ANGO $19.33
- CAPR $23.00
- AVG Volume (30 Days)
- ANGO 442.6K
- CAPR 1.2M
- Earning Date
- ANGO 10-02-2025
- CAPR 11-10-2025
- Dividend Yield
- ANGO N/A
- CAPR N/A
- EPS Growth
- ANGO N/A
- CAPR N/A
- EPS
- ANGO N/A
- CAPR N/A
- Revenue
- ANGO $300,718,000.00
- CAPR $13,392,150.00
- Revenue This Year
- ANGO $8.18
- CAPR N/A
- Revenue Next Year
- ANGO $5.15
- CAPR $7,894.07
- P/E Ratio
- ANGO N/A
- CAPR N/A
- Revenue Growth
- ANGO 2.73
- CAPR N/A
- 52 Week Low
- ANGO $6.63
- CAPR $5.68
- 52 Week High
- ANGO $13.50
- CAPR $20.75
- Technical
- Relative Strength Index (RSI)
- ANGO 51.33
- CAPR 43.68
- Support Level
- ANGO $11.53
- CAPR $6.00
- Resistance Level
- ANGO $12.18
- CAPR $6.41
- Average True Range (ATR)
- ANGO 0.35
- CAPR 0.35
- MACD
- ANGO -0.09
- CAPR -0.00
- Stochastic Oscillator
- ANGO 23.57
- CAPR 7.41
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.